Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor
BioSpace
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to "restore re
pharminent
April 2, 2026 (Last updated: April 2, 2026)
BioSpace
With CBER director Vinay Prasad set to depart the agency at the end of the month, a coalition of patient groups and biotech executives penned a letter imploring the Trump administration to “restore re
